Short answer
Benitec Biopharma Inc. (BNTC) filed an 8-K current report with the SEC on November 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item EX-99.1 (Exhibit EX-99.1). Fiscal-quarter results for period ended September 30, 2026 announced.
Benitec Biopharma Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal-quarter results for period ended September 30, 2026 announced
- Operational update accompanies financial results
- Press release provided as Exhibit 99.1, containing the detailed figures and commentary
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Fiscal year-end shifted from June 30 to December 31, effective November 12, 2026
- Six-month transition period, July 1 through December 31, 2026, reported in a Transition Form 10-K
- Calendar-year reporting begins January 1, 2027, improving period comparability
- No Articles of Incorporation or Bylaws amendment required
Item EX-99.1 · Exhibit EX-99.1
- BB-301 interim data showed a 100% responder rate across six Cohort 1 and three Cohort 2 patients, with no serious adverse events reported
- Pivotal BB-301 study design targeted for Q1 2027, with trial initiation still planned for mid-2027
- Cash and equivalents $176.5 million at September 30, 2026, supporting continued development but not eliminating future financing risk
- R&D expense rose to $8.6 million from $3.4 million, reflecting accelerated BB-301 clinical investment
- Net loss widened to $12.9 million from $9.0 million, while shares outstanding increased to 49.5 million from 41.5 million weighted-average shares
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Benitec Biopharma Inc. 8-K filings
Get the next BNTC 8-K as it lands
Follow BNTC for push alerts, or ask the research agent what this filing means.